APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Enzalutamide Soft Capsules

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Enzalutamide Soft Capsules Market Outlook and Growth Opportunities 2026

Report ID 173988590427 December 2025193 pages

Choose your research edition.

Industry ResearchEnzalutamide Soft Capsules Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Enzalutamide Soft Capsules Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Enzalutamide Soft Capsules Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Enzalutamide Soft Capsules Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Enzalutamide Soft Capsules Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Enzalutamide Soft Capsules market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Enzalutamide Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Enzalutamide Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Enzalutamide Soft Capsules is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Enzalutamide Soft Capsules market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Enzalutamide Soft Capsules market include Aprazer Healthcare Pharma, Arechar Healthcare, Astellas Pharma, BDR Pharma, Glenmark Pharma, Intas Pharmaceuticals, Pfizer, Jiangsu Hansoh Pharmaceutical and Kelun Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Enzalutamide Soft Capsules market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Enzalutamide Soft Capsules and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Enzalutamide Soft Capsules sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Enzalutamide Soft Capsules market size, projected growth trends, production technologies, key applications, and end-use industries.

Enzalutamide Soft Capsules Segment by Company

Aprazer Healthcare Pharma

Arechar Healthcare

Astellas Pharma

BDR Pharma

Glenmark Pharma

Intas Pharmaceuticals

Pfizer

Jiangsu Hansoh Pharmaceutical

Kelun Pharmaceutical

Qilu Pharmaceutical

PuraCap Pharmaceuticals

Shenyang Hongqi Pharmaceutical

Yichang Humanwell Pharmaceutical

Enzalutamide Soft Capsules Segment by Type

Original Drug

Generic Drug

Enzalutamide Soft Capsules Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Enzalutamide Soft Capsules Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Enzalutamide Soft Capsules status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Enzalutamide Soft Capsules market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Enzalutamide Soft Capsules significant trends, drivers, influence factors in global and regions.

6. To analyze Enzalutamide Soft Capsules competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Enzalutamide Soft Capsules market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Enzalutamide Soft Capsules and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Enzalutamide Soft Capsules.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Enzalutamide Soft Capsules market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Enzalutamide Soft Capsules industry.

Chapter 3: Detailed analysis of Enzalutamide Soft Capsules manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Enzalutamide Soft Capsules in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Enzalutamide Soft Capsules in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Enzalutamide Soft Capsules Industry Trends Table 2. Enzalutamide Soft Capsules Industry Drivers Table 3. Enzalutamide Soft Capsules Industry Opportunities and Challenges Table 4. Enzalutamide Soft Capsules Industry Restraints Table 5. Global Enzalutamide Soft Capsules Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Enzalutamide Soft Capsules Revenue Share by Company (2021-2026) Table 7. Global Enzalutamide Soft Capsules Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Enzalutamide Soft Capsules Sales Volume Share by Company (2021-2026) Table 9. Global Enzalutamide Soft Capsules Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Enzalutamide Soft Capsules Company Ranking, (2024-2026) & (USD Million) Table 11. Global Enzalutamide Soft Capsules Key Company Manufacturing Base & Headquarters Table 12. Global Enzalutamide Soft Capsules Company, Product Type & Application Table 13. Global Enzalutamide Soft Capsules Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Enzalutamide Soft Capsules by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Original Drug Table 18. Significant Companies of Generic Drug Table 19. Global Enzalutamide Soft Capsules Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Enzalutamide Soft Capsules Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Enzalutamide Soft Capsules Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Enzalutamide Soft Capsules Sales Volume Share by Type (2021-2026) Table 23. Global Enzalutamide Soft Capsules Sales Volume Share by Type (2027-2032) Table 24. Global Enzalutamide Soft Capsules Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Enzalutamide Soft Capsules Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Enzalutamide Soft Capsules Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Enzalutamide Soft Capsules Sales Value Share by Type (2021-2026) Table 28. Global Enzalutamide Soft Capsules Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Other Table 32. Global Enzalutamide Soft Capsules Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Enzalutamide Soft Capsules Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Enzalutamide Soft Capsules Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Enzalutamide Soft Capsules Sales Volume Share by Application (2021-2026) Table 36. Global Enzalutamide Soft Capsules Sales Volume Share by Application (2027-2032) Table 37. Global Enzalutamide Soft Capsules Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Enzalutamide Soft Capsules Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Enzalutamide Soft Capsules Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Enzalutamide Soft Capsules Sales Value Share by Application (2021-2026) Table 41. Global Enzalutamide Soft Capsules Sales Value Share by Application (2027-2032) Table 42. Global Enzalutamide Soft Capsules Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Enzalutamide Soft Capsules Sales by Region (2021-2026) & (K Units) Table 44. Global Enzalutamide Soft Capsules Sales Market Share by Region (2021-2026) Table 45. Global Enzalutamide Soft Capsules Sales by Region (2027-2032) & (K Units) Table 46. Global Enzalutamide Soft Capsules Sales Market Share by Region (2027-2032) Table 47. Global Enzalutamide Soft Capsules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Enzalutamide Soft Capsules Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Enzalutamide Soft Capsules Sales Value Share by Region (2021-2026) Table 50. Global Enzalutamide Soft Capsules Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Enzalutamide Soft Capsules Sales Value Share by Region (2027-2032) Table 52. Global Enzalutamide Soft Capsules Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Enzalutamide Soft Capsules Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Enzalutamide Soft Capsules Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Enzalutamide Soft Capsules Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Enzalutamide Soft Capsules Sales by Country (2021-2026) & (K Units) Table 57. Global Enzalutamide Soft Capsules Sales Market Share by Country (2021-2026) Table 58. Global Enzalutamide Soft Capsules Sales by Country (2027-2032) & (K Units) Table 59. Global Enzalutamide Soft Capsules Sales Market Share by Country (2027-2032) Table 60. Global Enzalutamide Soft Capsules Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Enzalutamide Soft Capsules Sales Value Market Share by Country (2021-2026) Table 62. Global Enzalutamide Soft Capsules Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Enzalutamide Soft Capsules Sales Value Market Share by Country (2027-2032) Table 64. Aprazer Healthcare Pharma Company Information Table 65. Aprazer Healthcare Pharma Business Overview Table 66. Aprazer Healthcare Pharma Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Aprazer Healthcare Pharma Enzalutamide Soft Capsules Product Portfolio Table 68. Aprazer Healthcare Pharma Recent Development Table 69. Arechar Healthcare Company Information Table 70. Arechar Healthcare Business Overview Table 71. Arechar Healthcare Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Arechar Healthcare Enzalutamide Soft Capsules Product Portfolio Table 73. Arechar Healthcare Recent Development Table 74. Astellas Pharma Company Information Table 75. Astellas Pharma Business Overview Table 76. Astellas Pharma Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Astellas Pharma Enzalutamide Soft Capsules Product Portfolio Table 78. Astellas Pharma Recent Development Table 79. BDR Pharma Company Information Table 80. BDR Pharma Business Overview Table 81. BDR Pharma Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. BDR Pharma Enzalutamide Soft Capsules Product Portfolio Table 83. BDR Pharma Recent Development Table 84. Glenmark Pharma Company Information Table 85. Glenmark Pharma Business Overview Table 86. Glenmark Pharma Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Glenmark Pharma Enzalutamide Soft Capsules Product Portfolio Table 88. Glenmark Pharma Recent Development Table 89. Intas Pharmaceuticals Company Information Table 90. Intas Pharmaceuticals Business Overview Table 91. Intas Pharmaceuticals Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Intas Pharmaceuticals Enzalutamide Soft Capsules Product Portfolio Table 93. Intas Pharmaceuticals Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Pfizer Enzalutamide Soft Capsules Product Portfolio Table 98. Pfizer Recent Development Table 99. Jiangsu Hansoh Pharmaceutical Company Information Table 100. Jiangsu Hansoh Pharmaceutical Business Overview Table 101. Jiangsu Hansoh Pharmaceutical Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Jiangsu Hansoh Pharmaceutical Enzalutamide Soft Capsules Product Portfolio Table 103. Jiangsu Hansoh Pharmaceutical Recent Development Table 104. Kelun Pharmaceutical Company Information Table 105. Kelun Pharmaceutical Business Overview Table 106. Kelun Pharmaceutical Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Kelun Pharmaceutical Enzalutamide Soft Capsules Product Portfolio Table 108. Kelun Pharmaceutical Recent Development Table 109. Qilu Pharmaceutical Company Information Table 110. Qilu Pharmaceutical Business Overview Table 111. Qilu Pharmaceutical Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Qilu Pharmaceutical Enzalutamide Soft Capsules Product Portfolio Table 113. Qilu Pharmaceutical Recent Development Table 114. PuraCap Pharmaceuticals Company Information Table 115. PuraCap Pharmaceuticals Business Overview Table 116. PuraCap Pharmaceuticals Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. PuraCap Pharmaceuticals Enzalutamide Soft Capsules Product Portfolio Table 118. PuraCap Pharmaceuticals Recent Development Table 119. Shenyang Hongqi Pharmaceutical Company Information Table 120. Shenyang Hongqi Pharmaceutical Business Overview Table 121. Shenyang Hongqi Pharmaceutical Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Shenyang Hongqi Pharmaceutical Enzalutamide Soft Capsules Product Portfolio Table 123. Shenyang Hongqi Pharmaceutical Recent Development Table 124. Yichang Humanwell Pharmaceutical Company Information Table 125. Yichang Humanwell Pharmaceutical Business Overview Table 126. Yichang Humanwell Pharmaceutical Enzalutamide Soft Capsules Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Yichang Humanwell Pharmaceutical Enzalutamide Soft Capsules Product Portfolio Table 128. Yichang Humanwell Pharmaceutical Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Enzalutamide Soft Capsules Distributors List Table 132. Enzalutamide Soft Capsules Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Enzalutamide Soft Capsules Product Image Figure 2. Global Enzalutamide Soft Capsules Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Enzalutamide Soft Capsules Sales Value (2021-2032) & (US$ Million) Figure 4. Global Enzalutamide Soft Capsules Sales (2021-2032) & (K Units) Figure 5. Global Enzalutamide Soft Capsules Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Enzalutamide Soft Capsules Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Original Drug Image Figure 10. Generic Drug Image Figure 11. Global Enzalutamide Soft Capsules Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Enzalutamide Soft Capsules Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Enzalutamide Soft Capsules Sales Volume Share by Type (2021-2032) Figure 14. Global Enzalutamide Soft Capsules Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Enzalutamide Soft Capsules Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Enzalutamide Soft Capsules Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Retail Pharmacies Image Figure 19. Other Image Figure 20. Global Enzalutamide Soft Capsules Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Enzalutamide Soft Capsules Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Enzalutamide Soft Capsules Sales Volume Share by Application (2021-2032) Figure 23. Global Enzalutamide Soft Capsules Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Enzalutamide Soft Capsules Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Enzalutamide Soft Capsules Sales Value Share by Application (2021-2032) Figure 26. Global Enzalutamide Soft Capsules Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Enzalutamide Soft Capsules Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Enzalutamide Soft Capsules Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Enzalutamide Soft Capsules Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Enzalutamide Soft Capsules Sales Value (2021-2032) & (US$ Million) Figure 31. North America Enzalutamide Soft Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Enzalutamide Soft Capsules Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Enzalutamide Soft Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Enzalutamide Soft Capsules Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Enzalutamide Soft Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Enzalutamide Soft Capsules Sales Value (2021-2032) & (US$ Million) Figure 37. South America Enzalutamide Soft Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Enzalutamide Soft Capsules Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Enzalutamide Soft Capsules Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Enzalutamide Soft Capsules Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Enzalutamide Soft Capsules Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Aprazer Healthcare Pharma
  • Arechar Healthcare
  • Astellas Pharma
  • BDR Pharma
  • Glenmark Pharma
  • Intas Pharmaceuticals
  • Pfizer
  • Jiangsu Hansoh Pharmaceutical
  • Kelun Pharmaceutical
  • Qilu Pharmaceutical
  • PuraCap Pharmaceuticals
  • Shenyang Hongqi Pharmaceutical
  • Yichang Humanwell Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Enzalutamide Soft Capsules Sales Value (2021-2032)
  4. 1.2.2 Global Enzalutamide Soft Capsules Sales Volume (2021-2032)
  5. 1.2.3 Global Enzalutamide Soft Capsules Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Enzalutamide Soft Capsules Market Dynamics
  1. 2.1 Enzalutamide Soft Capsules Industry Trends
  2. 2.2 Enzalutamide Soft Capsules Industry Drivers
  3. 2.3 Enzalutamide Soft Capsules Industry Opportunities and Challenges
  4. 2.4 Enzalutamide Soft Capsules Industry Restraints
3 Enzalutamide Soft Capsules Market by Company
  1. 3.1 Global Enzalutamide Soft Capsules Company Revenue Ranking in 2025
  2. 3.2 Global Enzalutamide Soft Capsules Revenue by Company (2021-2026)
  3. 3.3 Global Enzalutamide Soft Capsules Sales Volume by Company (2021-2026)
  4. 3.4 Global Enzalutamide Soft Capsules Average Price by Company (2021-2026)
  5. 3.5 Global Enzalutamide Soft Capsules Company Ranking (2024-2026)
  6. 3.6 Global Enzalutamide Soft Capsules Company Manufacturing Base and Headquarters
  7. 3.7 Global Enzalutamide Soft Capsules Company Product Type and Application
  8. 3.8 Global Enzalutamide Soft Capsules Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Enzalutamide Soft Capsules Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Enzalutamide Soft Capsules Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Enzalutamide Soft Capsules Market by Type
  1. 4.1 Enzalutamide Soft Capsules Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Enzalutamide Soft Capsules Sales Volume by Type
  5. 4.2.1 Global Enzalutamide Soft Capsules Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Enzalutamide Soft Capsules Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Enzalutamide Soft Capsules Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Enzalutamide Soft Capsules Sales Value by Type
  9. 4.3.1 Global Enzalutamide Soft Capsules Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Enzalutamide Soft Capsules Sales Value by Type (2021-2032)
  11. 4.3.3 Global Enzalutamide Soft Capsules Sales Value Share by Type (2021-2032)
5 Enzalutamide Soft Capsules Market by Application
  1. 5.1 Enzalutamide Soft Capsules Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Enzalutamide Soft Capsules Sales Volume by Application
  6. 5.2.1 Global Enzalutamide Soft Capsules Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Enzalutamide Soft Capsules Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Enzalutamide Soft Capsules Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Enzalutamide Soft Capsules Sales Value by Application
  10. 5.3.1 Global Enzalutamide Soft Capsules Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Enzalutamide Soft Capsules Sales Value by Application (2021-2032)
  12. 5.3.3 Global Enzalutamide Soft Capsules Sales Value Share by Application (2021-2032)
6 Enzalutamide Soft Capsules Regional Sales and Value Analysis
  1. 6.1 Global Enzalutamide Soft Capsules Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Enzalutamide Soft Capsules Sales by Region (2021-2032)
  3. 6.2.1 Global Enzalutamide Soft Capsules Sales by Region: 2021-2026
  4. 6.2.2 Global Enzalutamide Soft Capsules Sales by Region (2027-2032)
  5. 6.3 Global Enzalutamide Soft Capsules Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Enzalutamide Soft Capsules Sales Value by Region (2021-2032)
  7. 6.4.1 Global Enzalutamide Soft Capsules Sales Value by Region: 2021-2026
  8. 6.4.2 Global Enzalutamide Soft Capsules Sales Value by Region (2027-2032)
  9. 6.5 Global Enzalutamide Soft Capsules Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Enzalutamide Soft Capsules Sales Value (2021-2032)
  12. 6.6.2 North America Enzalutamide Soft Capsules Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Enzalutamide Soft Capsules Sales Value (2021-2032)
  15. 6.7.2 Europe Enzalutamide Soft Capsules Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Enzalutamide Soft Capsules Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Enzalutamide Soft Capsules Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Enzalutamide Soft Capsules Sales Value (2021-2032)
  21. 6.9.2 South America Enzalutamide Soft Capsules Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Enzalutamide Soft Capsules Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Enzalutamide Soft Capsules Sales Value Share by Country, 2025 VS 2032
7 Enzalutamide Soft Capsules Country-level Sales and Value Analysis
  1. 7.1 Global Enzalutamide Soft Capsules Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Enzalutamide Soft Capsules Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Enzalutamide Soft Capsules Sales by Country (2021-2032)
  4. 7.3.1 Global Enzalutamide Soft Capsules Sales by Country (2021-2026)
  5. 7.3.2 Global Enzalutamide Soft Capsules Sales by Country (2027-2032)
  6. 7.4 Global Enzalutamide Soft Capsules Sales Value by Country (2021-2032)
  7. 7.4.1 Global Enzalutamide Soft Capsules Sales Value by Country (2021-2026)
  8. 7.4.2 Global Enzalutamide Soft Capsules Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Enzalutamide Soft Capsules Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Enzalutamide Soft Capsules Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Enzalutamide Soft Capsules Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aprazer Healthcare Pharma
  2. 8.1.1 Aprazer Healthcare Pharma Company Information
  3. 8.1.2 Aprazer Healthcare Pharma Business Overview
  4. 8.1.3 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aprazer Healthcare Pharma Enzalutamide Soft Capsules Product Portfolio
  6. 8.1.5 Aprazer Healthcare Pharma Recent Developments
  7. 8.2 Arechar Healthcare
  8. 8.2.1 Arechar Healthcare Company Information
  9. 8.2.2 Arechar Healthcare Business Overview
  10. 8.2.3 Arechar Healthcare Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Arechar Healthcare Enzalutamide Soft Capsules Product Portfolio
  12. 8.2.5 Arechar Healthcare Recent Developments
  13. 8.3 Astellas Pharma
  14. 8.3.1 Astellas Pharma Company Information
  15. 8.3.2 Astellas Pharma Business Overview
  16. 8.3.3 Astellas Pharma Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Enzalutamide Soft Capsules Product Portfolio
  18. 8.3.5 Astellas Pharma Recent Developments
  19. 8.4 BDR Pharma
  20. 8.4.1 BDR Pharma Company Information
  21. 8.4.2 BDR Pharma Business Overview
  22. 8.4.3 BDR Pharma Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 BDR Pharma Enzalutamide Soft Capsules Product Portfolio
  24. 8.4.5 BDR Pharma Recent Developments
  25. 8.5 Glenmark Pharma
  26. 8.5.1 Glenmark Pharma Company Information
  27. 8.5.2 Glenmark Pharma Business Overview
  28. 8.5.3 Glenmark Pharma Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Glenmark Pharma Enzalutamide Soft Capsules Product Portfolio
  30. 8.5.5 Glenmark Pharma Recent Developments
  31. 8.6 Intas Pharmaceuticals
  32. 8.6.1 Intas Pharmaceuticals Company Information
  33. 8.6.2 Intas Pharmaceuticals Business Overview
  34. 8.6.3 Intas Pharmaceuticals Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Intas Pharmaceuticals Enzalutamide Soft Capsules Product Portfolio
  36. 8.6.5 Intas Pharmaceuticals Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Enzalutamide Soft Capsules Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Jiangsu Hansoh Pharmaceutical
  44. 8.8.1 Jiangsu Hansoh Pharmaceutical Company Information
  45. 8.8.2 Jiangsu Hansoh Pharmaceutical Business Overview
  46. 8.8.3 Jiangsu Hansoh Pharmaceutical Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hansoh Pharmaceutical Enzalutamide Soft Capsules Product Portfolio
  48. 8.8.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  49. 8.9 Kelun Pharmaceutical
  50. 8.9.1 Kelun Pharmaceutical Company Information
  51. 8.9.2 Kelun Pharmaceutical Business Overview
  52. 8.9.3 Kelun Pharmaceutical Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Kelun Pharmaceutical Enzalutamide Soft Capsules Product Portfolio
  54. 8.9.5 Kelun Pharmaceutical Recent Developments
  55. 8.10 Qilu Pharmaceutical
  56. 8.10.1 Qilu Pharmaceutical Company Information
  57. 8.10.2 Qilu Pharmaceutical Business Overview
  58. 8.10.3 Qilu Pharmaceutical Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Qilu Pharmaceutical Enzalutamide Soft Capsules Product Portfolio
  60. 8.10.5 Qilu Pharmaceutical Recent Developments
  61. 8.11 PuraCap Pharmaceuticals
  62. 8.11.1 PuraCap Pharmaceuticals Company Information
  63. 8.11.2 PuraCap Pharmaceuticals Business Overview
  64. 8.11.3 PuraCap Pharmaceuticals Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 PuraCap Pharmaceuticals Enzalutamide Soft Capsules Product Portfolio
  66. 8.11.5 PuraCap Pharmaceuticals Recent Developments
  67. 8.12 Shenyang Hongqi Pharmaceutical
  68. 8.12.1 Shenyang Hongqi Pharmaceutical Company Information
  69. 8.12.2 Shenyang Hongqi Pharmaceutical Business Overview
  70. 8.12.3 Shenyang Hongqi Pharmaceutical Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shenyang Hongqi Pharmaceutical Enzalutamide Soft Capsules Product Portfolio
  72. 8.12.5 Shenyang Hongqi Pharmaceutical Recent Developments
  73. 8.13 Yichang Humanwell Pharmaceutical
  74. 8.13.1 Yichang Humanwell Pharmaceutical Company Information
  75. 8.13.2 Yichang Humanwell Pharmaceutical Business Overview
  76. 8.13.3 Yichang Humanwell Pharmaceutical Enzalutamide Soft Capsules Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Yichang Humanwell Pharmaceutical Enzalutamide Soft Capsules Product Portfolio
  78. 8.13.5 Yichang Humanwell Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Enzalutamide Soft Capsules Value Chain Analysis
  2. 9.1.1 Enzalutamide Soft Capsules Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Enzalutamide Soft Capsules Sales Mode & Process
  6. 9.2 Enzalutamide Soft Capsules Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Enzalutamide Soft Capsules Distributors
  9. 9.2.3 Enzalutamide Soft Capsules Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst